Cell Biology Department, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Center for Neuroscience, Shantou University Medical College, Shantou, China.
Front Immunol. 2021 May 13;12:682415. doi: 10.3389/fimmu.2021.682415. eCollection 2021.
Gliomas, including brain lower grade glioma (LGG) and glioblastoma multiforme (GBM), are the most common primary brain tumors in the central nervous system. Neuregulin (NRG) family proteins belong to the epidermal growth factor (EGF) family of extracellular ligands and they play an essential role in both the central and peripheral nervous systems. However, roles of NRGs in gliomas, especially their effects on prognosis, still remain to be elucidated. In this study, we obtained raw counts of RNA-sequencing data and corresponding clinical information from 510 LGG and 153 GBM samples from The Cancer Genome Atlas (TCGA) database. We analyzed the association of NRG1-4 expression levels with tumor immune microenvironment in LGG and GBM. GSVA (Gene Set Variation Analysis) was performed to determine the prognostic difference of NRGs gene set between LGG and GBM. ROC (receiver operating characteristic) curve and the nomogram model were constructed to estimate the prognostic value of NRGs in LGG and GBM. The results demonstrated that NRG1-4 were differentially expressed in LGG and GBM in comparison to normal tissue. Immune score analysis revealed that NRG1-4 were significantly related to the tumor immune microenvironment and remarkably correlated with immune cell infiltration. The investigation of roles of mA (N6-methyladenosine, mA)-related genes in gliomas revealed that NRGs were prominently involved in mA RNA modification. GSVA score showed that NRG family members are more associated with prognosis in LGG compared with GBM. Prognostic analysis showed that NRG3 and NRG1 can serve as potential independent biomarkers in LGG and GBM, respectively. Moreover, GDSC drug sensitivity analysis revealed that NRG1 was more correlated with drug response compared with other NRG subtypes. Based on these public databases, we preliminarily identified the relationship between NRG family members and tumor immune microenvironment, and the prognostic value of NRGs in gliomas. In conclusion, our study provides comprehensive roles of NRG family members in gliomas, supporting modulation of NRG signaling in the management of glioma.
神经调节蛋白(NRG)家族蛋白属于表皮生长因子(EGF)家族的细胞外配体,它们在中枢和外周神经系统中都发挥着重要作用。然而,NRG 在神经胶质瘤中的作用,尤其是它们对预后的影响,仍有待阐明。在这项研究中,我们从癌症基因组图谱(TCGA)数据库中获得了 510 例低级别神经胶质瘤(LGG)和 153 例胶质母细胞瘤(GBM)样本的 RNA 测序数据的原始计数和相应的临床信息。我们分析了 NRG1-4 表达水平与 LGG 和 GBM 肿瘤免疫微环境的关联。进行了 GSVA(基因集变异分析)以确定 NRGs 基因集在 LGG 和 GBM 之间的预后差异。构建了 ROC(接收者操作特征)曲线和诺模图模型,以估计 NRGs 在 LGG 和 GBM 中的预后价值。结果表明,与正常组织相比,NRG1-4 在 LGG 和 GBM 中差异表达。免疫评分分析表明,NRG1-4 与肿瘤免疫微环境显著相关,与免疫细胞浸润显著相关。对 mA(N6-甲基腺苷,mA)相关基因在神经胶质瘤中的作用的研究表明,NRGs 显著参与 mA RNA 修饰。GSVA 评分显示,NRG 家族成员与 LGG 的预后相关性高于 GBM。预后分析表明,NRG3 和 NRG1 可分别作为 LGG 和 GBM 的潜在独立生物标志物。此外,GDSC 药物敏感性分析表明,NRG1 与药物反应的相关性高于其他 NRG 亚型。基于这些公共数据库,我们初步确定了 NRG 家族成员与肿瘤免疫微环境的关系,以及 NRGs 在神经胶质瘤中的预后价值。总之,我们的研究提供了 NRG 家族成员在神经胶质瘤中的全面作用,支持调节 NRG 信号在神经胶质瘤管理中的作用。